Genomic Health, Inc. (NASDAQ:GHDX) Insider Sells $458,850.15 in Stock

Genomic Health, Inc. (NASDAQ:GHDX) insider James J. Vaughn sold 8,745 shares of the business’s stock in a transaction dated Thursday, June 6th. The stock was sold at an average price of $52.47, for a total transaction of $458,850.15. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Shares of GHDX stock opened at $51.13 on Wednesday. The stock has a market capitalization of $1.90 billion, a price-to-earnings ratio of 48.70 and a beta of 1.05. The company has a debt-to-equity ratio of 0.19, a quick ratio of 5.67 and a current ratio of 5.67. Genomic Health, Inc. has a 52 week low of $48.00 and a 52 week high of $92.18.

Genomic Health (NASDAQ:GHDX) last posted its quarterly earnings results on Tuesday, May 7th. The medical research company reported $0.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.29 by $0.05. Genomic Health had a net margin of 10.35% and a return on equity of 18.70%. The company had revenue of $108.80 million for the quarter, compared to analyst estimates of $106.75 million. During the same quarter in the previous year, the firm posted ($0.11) earnings per share. The company’s quarterly revenue was up 17.5% compared to the same quarter last year. Research analysts predict that Genomic Health, Inc. will post 1.44 earnings per share for the current year.



Several hedge funds and other institutional investors have recently bought and sold shares of GHDX. Renaissance Technologies LLC raised its position in shares of Genomic Health by 22.2% in the first quarter. Renaissance Technologies LLC now owns 2,379,500 shares of the medical research company’s stock valued at $166,684,000 after purchasing an additional 432,400 shares during the period. Norges Bank bought a new stake in shares of Genomic Health in the fourth quarter valued at approximately $20,975,000. Man Group plc raised its position in shares of Genomic Health by 104.1% in the first quarter. Man Group plc now owns 570,981 shares of the medical research company’s stock valued at $39,997,000 after purchasing an additional 291,160 shares during the period. Fiera Capital Corp bought a new stake in shares of Genomic Health in the first quarter valued at approximately $20,134,000. Finally, FMR LLC raised its position in shares of Genomic Health by 83.8% in the fourth quarter. FMR LLC now owns 550,627 shares of the medical research company’s stock valued at $35,466,000 after purchasing an additional 251,085 shares during the period. 95.75% of the stock is currently owned by institutional investors.

Several analysts have commented on the stock. BidaskClub lowered shares of Genomic Health from a “buy” rating to a “hold” rating in a research report on Saturday, March 30th. Canaccord Genuity reaffirmed a “buy” rating and issued a $85.00 price objective (down previously from $95.00) on shares of Genomic Health in a research report on Wednesday, May 8th. Deutsche Bank lowered their price objective on shares of Genomic Health from $80.00 to $55.00 and set a “hold” rating on the stock in a research report on Thursday, May 30th. Needham & Company LLC reaffirmed a “strong-buy” rating and issued a $69.00 price objective (down previously from $97.00) on shares of Genomic Health in a research report on Thursday, May 9th. Finally, ValuEngine lowered shares of Genomic Health from a “buy” rating to a “hold” rating in a research report on Wednesday, May 8th. Eleven analysts have rated the stock with a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company. Genomic Health presently has a consensus rating of “Hold” and an average target price of $62.63.

ILLEGAL ACTIVITY WARNING: This article was originally reported by Dakota Financial News and is the sole property of of Dakota Financial News. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://dakotafinancialnews.com/2019/06/12/genomic-health-inc-nasdaqghdx-insider-sells-458850-15-in-stock.html.

Genomic Health Company Profile

Genomic Health, Inc, a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions.

Further Reading: Growth and Income Funds

Insider Buying and Selling by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.